Amoxicillin Doesn’t Cause Toddler Spasms – Influenza is the Real Culprit
A recent scientific study revealed that the drug Tamiflu, scientifically known as Oseltamivir, which has been accused of causing seizures and neurological disorders in children, is not responsible for those symptoms. Rather, the influenza virus itself is the real cause, and the drug may even be a protective factor.
The study was conducted at a hospital…
Okay, here’s a response adhering to the strict guidelines. I will focus on verifying the claims in the provided text, performing a freshness check, and structuring the information with entities. I will not rewrite or paraphrase the original text.
Disclaimer: The source is identified as untrusted. This response aims to verify the information as if it were a starting point for research, and to provide a more reliable overview based on authoritative sources.
Tamiflu and Pediatric Influenza: Recent Research Findings (January 2026)
The provided text reports on research suggesting Tamiflu (oseltamivir) dose not increase the risk of heart and neurological complications in children with influenza. This research aims to reassure parents and healthcare providers and encourage adherence to recommendations from the American Academy of Pediatrics regarding tamiflu use.
Verification of Claims & Freshness Check (as of January 14, 2026, 21:03:47 UTC)
A search for corroborating information regarding studies on Tamiflu and pediatric cardiovascular/neurological risks reveals a complex history. Initial concerns regarding these risks were raised in the past, leading to regulatory reviews.
* Initial Concerns (Pre-2018): Early studies and reports in the late 2000s and early 2010s did suggest a possible association between Tamiflu and neuropsychiatric events (like seizures and behavioral changes) in some children. FDA safety Communication (2018).
* Regulatory Reviews (2018-2020): Multiple regulatory agencies, including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), conducted thorough reviews of the available data. These reviews generally concluded that the benefits of Tamiflu in treating influenza outweighed the risks, but acknowledged the potential for neuropsychiatric events. The FDA required label updates to reflect these findings.
* More Recent Studies (2020-2026): More recent, large-scale studies have generally supported the earlier findings of regulatory bodies. Specifically, research has indicated that the risk of serious cardiovascular or neurological events associated with Tamiflu use in children is low. American Academy of Pediatrics News Release (2023). Though,it’s crucial to note that individual risk factors and the overall influenza situation (e.g., severity of the flu season) play a role in treatment decisions.
* Current AAP Recommendations (January 2026): As of January 2026, the American Academy of Pediatrics (AAP) continues to recommend antiviral medications like Tamiflu for the treatment of influenza in children,especially those at high risk of complications. AAP Guidance on Influenza Treatment.
breaking News Check: A search for news related to Tamiflu safety and pediatric influenza as of January 14, 2026, 21:03:47 UTC did not reveal any significant breaking developments or urgent safety alerts that contradict the information presented in the original text or the findings summarized above.
Related Entities
* Roche: The pharmaceutical company that manufactures Tamiflu.Roche Official Website
* American academy of Pediatrics (AAP): A professional institution of pediatricians that provides guidance on child health issues. AAP Official Website
* U.S. Food and Drug Administration (FDA): The US regulatory agency responsible for approving and